TherageniX utilizes a virus-free peptide-based technology to deliver plasmid DNA that instructs the body to produce proteins essential for tissue regeneration. This approach addresses the challenge of inadequate tissue repair due to disease, injury, or aging by enhancing the regeneration process during surgical procedures.
Funding
$1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IUFounders
Product
Problem
The body's natural ability to repair and regenerate tissues is often insufficient due to disease, injury, or aging, leading to impaired healing and the need for intervention. Current bone grafting procedures, frequently used to address these issues, can face challenges such as rejection, infection, and inadequate regeneration.
Solution
TherageniX is developing a virus-free, peptide-based technology for targeted gene delivery to enhance tissue regeneration. The technology uses plasmid DNA and engineered peptides to form nanocomplexes that deliver DNA cargo into cells. By delivering regenerative factor genes, such as BMPs and VEGF, intra-operatively with autologous bone marrow cells, TherageniX aims to improve bone regeneration and reduce donor site trauma. The technology can also be combined with existing biomaterials to improve patient access.
Target Audience
The primary target audience includes surgeons performing bone grafting procedures and patients requiring enhanced tissue regeneration due to injury, disease, or aging.
Features
- Virus-free peptide-based technology for safe and efficient gene delivery
- Nanocomplexes composed of plasmid DNA and engineered peptides
- Customizable peptides to improve transduction efficiency
- Delivery of regenerative factor genes (e.g., BMPs and VEGF)
- Potential for combination with existing biomaterials
- Enhanced safety profile compared to viral gene therapies
- Higher versatility and lower costs than traditional methods